56.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com
What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
What are Protagonist Therapeutics Inc. company’s key revenue driversGet alerts on high-potential stock breakouts - jammulinksnews.com
What institutional investors are buying Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com
Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it
Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN
Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia
What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News
CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks
Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com Nigeria
Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):